BioSpace News Archive

As if attempting to steal hard-won research wasn’t bad enough, hackers are now hitting people where it really hurts – with e-documents containing malicious code embedded in false offers of employment.

Check out some news happening today around the biopharma industry.

What do you think is how much time is required for vaccine development? In a pandemic, the timeline is less than normal. Want to know why? Read the article and find.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

South Korea’s biotechnology company specializing in molecular diagnostics, Seegene Inc. said Thursday that the extraction-free application of Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay is now available in Europe.

Memo Therapeutics AG, an innovator in the field of antibody discovery and development, announced that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has demonstrated outstanding efficacy in an animal model of the infection, both in a treatment and a prophylactic setting.

Updates on Aplio i-series Offer Depth and Detail in Imaging with Enhanced Comfort to Help Improve Workflow

Teleflex Incorporated announced that it was named the winner of MedReps.com’s 10th Annual Best Places to Work in Medical Sales 2021 survey for the Large Category Best Medical Device Companies and placed second in the Overall Category, covering Best Medical Device Companies, Best Pharma Companies and Best Biotech Companies.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced positive results from its good laboratory practice (GLP) preclinical toxicology study of EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment using its proprietary bioerodible Durasert® technology for wet age-related macular degeneration (wet AMD).

Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines which act in the small intestine with systemic effects, today announced that it is recruiting ahead of schedule and has completed enrollment of the patients necessary for the interim data readout in the Phase 2 clinical trial evaluating EDP1815 for the treatment of mild to moderate psoriasis